证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-004 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 换股价格调整的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到公司控股 股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达集团 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第一期可 交债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 4 月 11 日完成第一期可交债的发行。本 期可交债简称"23 创 01EB"，债券代码为"137171"，发行规模 9.1 亿元，债券 期限 3 年。具体内容详见公司于 2023 年 4 月 12 日在上海证券交易所网站披露的 临 2023-019 号公告。 "23 创 01EB"换股期为 2023 年 10 月 12 日至 2026 年 4 月 11 日。2025 年 ...

Core Viewpoint - The announcement from Zhenbao Island indicates a decrease in the shareholding percentage of its controlling shareholder, Heilongjiang Chuangda Group, due to the conversion of bonds into shares, impacting the ownership structure of the company [1] Group 1 - Zhenbao Island received a notification from its controlling shareholder, Heilongjiang Chuangda Group, regarding the issuance of non-public exchangeable bonds aimed at professional investors [1] - The bondholders converted a total of 8,842,536 shares between October 24, 2025, and January 12, 2026, leading to a passive decrease in Chuangda Group's shareholding [1] - As a result of the conversion, Chuangda Group's ownership in the company decreased from 57.92% to 56.98%, marking a change that touches the 1% scale integer [1]

证券代码：603567 证券简称：珍宝岛 公告编号：临2026-003 2.信息披露义务人信息 黑龙江珍宝岛药业股份有限公司 关于控股股东权益变动触及 1%刻度的提示性公告 黑龙江创达集团有限公司保证向本公司提供的信息真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少☑ | | --- | --- | --- | --- | | 权益变动前合计比例 | 57.92% | | | | 权益变动后合计比例 | 56.98% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否☑ | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | ☑控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | ...

Core Viewpoint - The announcement from Zhenbao Island indicates that the controlling shareholder, Chuangda Group, will exchange 8.842536 million shares of convertible bonds, reducing its shareholding from 57.92% to 56.98% between October 24, 2025, and January 12, 2026. This change is due to the conversion of convertible bonds and does not affect the controlling shareholder or actual controller of the company, nor does it trigger a mandatory bid or require additional disclosure [1]. Group 1 - The exchange of convertible bonds will lead to a decrease in the controlling shareholder's stake from 57.92% to 56.98% [1] - The change in shareholding is attributed to the conversion of convertible bonds, which is currently in the conversion period [1] - The company will disclose any subsequent changes in equity as required by regulations [1]

Group 1 - The core viewpoint of the news is that Zhenbaodao's stock price has experienced fluctuations, with a recent decline of 2.05% and a total market value of 8.977 billion yuan [1] - As of January 13, Zhenbaodao's stock price is reported at 9.54 yuan per share, with a trading volume of 55.8049 million yuan and a turnover rate of 0.62% [1] - The company has seen a net outflow of main funds amounting to 1.4718 million yuan, with large orders accounting for 9.27% of purchases and 11.90% of sales [1] Group 2 - Zhenbaodao's stock price has increased by 6.83% year-to-date, with a 3.58% rise over the last five trading days, but has decreased by 3.15% over the last 20 days and 18.95% over the last 60 days [2] - The company, established on October 28, 1996, and listed on April 24, 2015, specializes in the research, production, and sales of high-end traditional Chinese medicine [2] - The main revenue sources for Zhenbaodao include 84.82% from the sale of proprietary medicines, 7.13% from purchased medicinal materials, and 5.11% from purchased pharmaceuticals [2] Group 3 - As of September 30, the number of shareholders for Zhenbaodao is 20,900, a decrease of 2.72% from the previous period, with an average of 44,969 circulating shares per person, an increase of 2.80% [2] - For the period from January to September 2025, Zhenbaodao reported a revenue of 918 million yuan, a year-on-year decrease of 54.71%, and a net profit attributable to shareholders of -373 million yuan, a year-on-year decrease of 193.81% [2] Group 4 - Zhenbaodao has distributed a total of 1.302 billion yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3]

Group 1 - The core point of the article is that Zhenbao Island has reported the number of A-share shareholders as of January 10, 2026, which stands at 23,508 households [2]

Group 1 - The company announced that it has not provided guarantees for its controlling shareholders, actual controllers, or their related parties [2] - The company confirmed that there are no overdue guarantees [2]

证券代码：603567 证券简称：珍宝岛 公告编号：临2026-002 黑龙江珍宝岛药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | | 实际为其提供的 | | 是否在前期预计 | 本次担保是否有 | | --- | --- | --- | --- | --- | --- | | | 本次担保金额 | 担保余额（不含本 次担保金额） | | 额度内 | 反担保 | | 黑龙江珍宝岛医药 贸易有限公司 | 8,500.00 万元 | 25,500.00 | 万元 | 是 | 否 | | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 | 174,976 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 22.43 | | | □担保金额（含本次）超过上市公司最近一 期经审计净资产 50% □对外担保总额（含本次）超过上市公司最 | | | ...

Group 1 - The core point of the article is that the company, Zhenbao Island, has reported that as of December 31, 2025, the number of A-share shareholders will be 23,207 [2]

证券代码：603567 证券简称：珍宝岛 公告编号：临2026-001 黑龙江珍宝岛药业股份有限公司 关于为全资子公司提供担保进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保金额 | 实际为其提供的 担保余额（不含本 次担保金额） | | 是否在前期预计 额度内 | 本次担保是否有 反担保 | | --- | --- | --- | --- | --- | --- | | 亳州中药材商品交 易中心有限公司 | 14,000.00 万元 | 19,500.00 | 万元 | 是 | 否 | 对外担保逾期的累计金额（万元） 0 截至本公告日上市公司及其控股 子公司对外担保总额（万元） 174,976 对外担保总额占上市公司最近一 期经审计净资产的比例（%） 22.43 特别风险提示 □担保金额（含本次）超过上市公司最近一 期经审计净资产 50% □对外担保总额（含本次）超过上市公司最 近一期经审计净资产 100% □对合并报表外单位担保总额（含本次）达 ...